Bostwick Laboratories is a biotechnology and health care company founded in 1999 and headquartered in the United States. Specializing in anatomic and clinical pathology laboratory services with a focus on cancer monitoring and diagnosis, Bostwick Laboratories has established itself as a leader in urologic anatomic pathology. The company is also expanding its presence in the dermatology, gastroenterology, gynecology, nephrology, and hematology sectors.
Under the leadership of CEO Martin Stefanelli, Bostwick Laboratories is committed to delivering high-quality pathology services and support to physicians and patients who demand absolute confidence in their results. Their dedication to providing world-class pathology services has attracted significant attention from investors. The company received a Private Equity Round investment on 25 October 2011, with Metalmark Capital being the key investor.
Bostwick Laboratories stands out in the industry for its comprehensive range of pathology services and its commitment to excellence in cancer diagnosis. Its focus on precision and accuracy aligns with the increasing demand for reliable diagnostic solutions. With a solid track record supported by investments from prominent firms, the company is well-positioned to continue its growth and make a significant impact in the field of pathology and cancer diagnosis.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Private Equity Round | Unknown | 1 | Metalmark Capital | 25 Oct 2011 |
No recent news or press coverage available for Bostwick Laboratories.
We care about your data, and we'd love to use cookies make your experience better.
